Lei Jianping on May 14
Jiangxi Yimai Sunshine Group Co., Ltd. (hereinafter referred to as "Yimai Sunshine") has updated its prospectus and is preparing to be listed on the Hong Kong Stock Exchange.
Yimai Sunshine submitted its prospectus for the first time in May 2023, and at present, it has been approved by the China Securities Regulatory Commission for overseas IPO filing.
The annual revenue is 929 million
Yimai Sunshine specializes in the investment and operation of medical imaging centers, the development of medical imaging cloud platform technology, the cultivation of medical imaging talents, and the services of medical imaging industry chain. The core business includes imaging center services, imaging empowerment solutions, and Yimai cloud services.
Yimai Sunshine mainly generates revenue through medical imaging services and solutions:
1. Imaging center service. Yimai Sunshine operates its own medical imaging center and provides a number of imaging examination and diagnosis services, or provides operation and management services for partner medical imaging centers.
2. Image empowerment solutions. In 2019, Yimai Sunshine began to provide customers with image empowerment solutions. In order to maximize the value of such equipment, epulse Sunshine provides them with a series of supporting modular empowerment solutions.
3. Yimai cloud service. In order to support the development of the imaging center service business, e-pulse has developed the e-pulse cloud platform to provide development impetus for the internal business development, information management and data-driven operation of e-pulse sunshine. In 2018, as ePulse Solar's products and services continued to mature and develop, e-pulse Sunshine commercialized e-pulse cloud services and provided services to the medical imaging industry in China under the brand of e-pulse Solarity.
According to the prospectus, Yimai Sunshine's revenue in 2021, 2022, and 2023 will be 592 million yuan, 784 million yuan, and 929 million yuan respectively; The gross profit was 175 million yuan, 240 million yuan and 333 million yuan respectively.
Yimai Sunshine's annual profits in 2020, 2021, and 2022 will be -382 million yuan, -15.06 million yuan, and 36.57 million yuan respectively; The adjusted profit was -70.82 million yuan, -5.45 million yuan and 60 million yuan respectively.
As of December 31, 2023, the cash and cash equivalents held by Yimai Sunshine were $189 million, compared to $340 million in the same period last year.
京东健康与OrbiMed是股东
The executive directors of Yimai Sunshine are Xu Hark, Chen Chaoyang, Ms. He Yingfei and Feng Xian; The non-executive directors are Liu Forest and Mao Xiaojun; The independent non-executive directors are Wu Xiaohui, Luo Yi and Yuan Jun.
Before the IPO, Nanchang Yimai held 17.4562% of the shares, Beijing Goldman Sachs held 9.1234% of the shares, Baishan Investment held 6.5167% of the shares, Beijing Renren held 5.6986% of the shares, and Fenyong Technology held 5.5% of the shares;
Wang Shihe holds 5.2463%, Gu Junjun holds 5.2464%, JD Yingzheng, a subsidiary of JD Health, holds 4.7788%, Ganjiang Development holds 4.3009%, Zhongjin Zhihe holds 4.1667%, Ningbo Languan holds 3.3419%, Beijing Yimai holds 2.8546%, CICC Yingrun holds 2.7807%, and Hi-Tech Xinjun Growth Phase I holds 2.6501%;
Zhihe Phase II holds 2.3894%, Hangzhou Jingxin holds 2.1723%, OrbiMed's WWH holds 2.0043%, Beijing Shengzexin holds 1.9550%, Hi-Tech Venture holds 1.0079%, Xiaoying Investment holds 1.0026%, Shaanxi Hongrui holds 0.9071%, and Yu Kaitao and Zhou Xiaoyan hold 0.8863% respectively.
Beijing Meiyue Consulting holds 0.7505%, Beijing Huayu holds 0.6517%, Jiangxi State Holdings holds 0.6315%, Ningbo Zhuda holds 0.5442%, Zhao Wenbing holds 0.5213%, Yang Jun holds 0.4627%, Luo Lifang and Shanghai Liying hold 0.4431% respectively, OGF and ONH hold 0.4295% respectively, and Hi-Tech Xinjun Innovation and Nuowei Assets hold 0.4031% respectively.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.